Therapeutic areas: Diabetes, Obesity
Novo Nordisk reps manage the GLP-1 wave from the epicenter — Ozempic for T2D, Wegovy for obesity, and newly approved Wegovy HD (7.2mg) delivering 20.7% weight loss. Reps navigate payer access complexity, supply chain pressures, and multi-SKU portfolio management in a category that has fundamentally shifted primary care conversations.
Key products: Ozempic, Wegovy, Rybelsus, Victoza, Saxenda
Novo Nordisk reps manage the GLP-1 wave from the epicenter — Ozempic for T2D, Wegovy for obesity, and newly approved Wegovy HD (7.2mg) delivering 20.7% weight loss. Reps navigate payer access complexi